BELLICUM PHARMACEUTICALS INC's ticker is BLCM and the CUSIP is 079481107. A total of 94 filers reported holding BELLICUM PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $197,000 | +15.2% | 58,600 | 0.0% | 0.00% | – |
| Q4 2018 | $171,000 | -52.6% | 58,600 | 0.0% | 0.00% | – |
| Q3 2018 | $361,000 | -16.4% | 58,600 | 0.0% | 0.00% | – |
| Q2 2018 | $432,000 | +48.5% | 58,600 | +32.3% | 0.00% | – |
| Q1 2018 | $291,000 | -22.0% | 44,300 | 0.0% | 0.00% | – |
| Q4 2017 | $373,000 | -27.1% | 44,300 | 0.0% | 0.00% | -100.0% |
| Q3 2017 | $512,000 | -1.0% | 44,300 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $517,000 | -5.5% | 44,300 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $547,000 | +37.1% | 44,300 | +51.2% | 0.00% | 0.0% |
| Q4 2016 | $399,000 | -31.6% | 29,300 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $583,000 | +53.4% | 29,300 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $380,000 | +19.1% | 29,300 | -17.0% | 0.00% | 0.0% |
| Q1 2016 | $319,000 | -45.6% | 35,300 | +22.1% | 0.00% | 0.0% |
| Q4 2015 | $586,000 | +39.5% | 28,900 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $420,000 | +181.9% | 28,900 | +312.9% | 0.00% | – |
| Q2 2015 | $149,000 | – | 7,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 1,051,441 | $3,070,000 | 0.79% |
| X-Square Capital, LLC | 109,832 | $321,000 | 0.25% |
| KNOTT DAVID M | 111,427 | $325,000 | 0.15% |
| ARK Investment Management | 1,033,491 | $3,018,000 | 0.12% |
| Baker Brothers Advisors | 2,677,818 | $7,819,000 | 0.06% |
| HARVEY CAPITAL MANAGEMENT INC | 31,200 | $91,000 | 0.05% |
| DAFNA Capital Management LLC | 30,000 | $88,000 | 0.04% |
| WASATCH ADVISORS LP | 953,368 | $2,784,000 | 0.04% |
| FRANKLIN STREET ADVISORS INC /NC | 51,415 | $150,000 | 0.02% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,000,000 | $2,920,000 | 0.02% |